Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
TheBody.com/TheBodyPRO.com cover the XVIII International AIDS Conference (AIDS 2010)
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
Medical News

Study Finds PrEP Is Safe in Gay and Bi Men

July 29, 2010

Animal studies have suggested that antiretroviral drugs taken before exposure to HIV may prevent infection. One pre-exposure prophylaxis (PrEP) candidate, proved safe in a new CDC study presented Friday at the 18th International AIDS Conference in Vienna.

Advertisement

The double-blinded study involved 400 HIV-negative men who have sex with men (MSM) and reported having anal sex at least once in the previous year. Of the MSM, who were recruited from Atlanta, San Francisco, and Boston, 373 initiated the drug trial. Median age was 39; 73 percent were white, 15 percent African American, 4 percent Asian/Pacific Islander, and 9 percent Hispanic.

The men were randomized to receive either once-daily oral tenofovir or placebo at enrollment or after a nine-month delay. All subjects were regularly tested for HIV and received intensive HIV prevention counseling and condoms throughout the study.

"This study was not designed to detect efficacy of [tenofovir] in preventing HIV infection," the authors wrote in their conclusion. Seven study participants seroconverted: four from the placebo arm, including one HIV-negative at enrollment but subsequently found to be acutely infected, and three in the delayed PrEP group before they had initiated tenofovir.

The men taking tenofovir did not experience significant biomedical safety issues compared with the placebo group, found Dr. Lisa Grohskopf and colleagues. Early results from an ongoing review suggested that the men taking pills did not seem to forego condom use or take more HIV risks.

"We didn't find any increased risk of harm in medical terms, and on the behavioral side the preliminary work we've done also suggests there is no increased risk," Grohskopf said.

Back to other news for July 2010

Adapted from:
POZ Magazine
07.26.2010; David Evans


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More News and Research on HIV Medications for HIV Prevention

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:



Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

AIDS 2010
Home
Choose a Topic:
Previous Conferences

Advertisement